

## Message Text

UNCLASSIFIED

PAGE 01 STATE 134799

61

ORIGIN OES-05

INFO OCT-01 EUR-12 ISO-00 HEW-06 EB-07 COME-00 TRSE-00

PRS-01 AID-05 CIAE-00 INR-07 NSAE-00 L-03 H-02 FTC-01

/050 R

DRAFTED BY OES/SCI/BMP:MBEAUBIEN

APPROVED BY OES/SCI/BMP:AERICHMOND

EUR/CE:DANDERSON

----- 123367

R 101625Z JUN 75

FM SECSTATE WASHDC

TO AMEMBASSY BONN

UNCLAS STATE 134799

E.O. 11652: N/A

TAGS: ETRD, TBIO, PINT, OTRA, GW

SUBJECT: U.S. PHARMACEUTICAL REGULATION: STUDY TOUR  
OF FRG PARLIAMENTARIANS

REF: BONN 8474

1. EARLY SEPTEMBER TIME FOR VISIT BY FRG PARLIAMENTARIANS  
APPEARS VERY SUITABLE TO MAJOR GROUPS LISTED AND CONTACTED.  
DUE TO RECESS, CONGRESSIONAL VISITS WOULD HAVE TO BE  
SEPTEMBER 4 OR AFTER. VISITS TO BOTH FEDERAL TRADE  
COMMISSION AND CONSUMER PRODUCT SAFETY COMMISSION WOULD BE  
APPROPRIATE AS BOTH INVOLVED IN ASPECTS OF INTEREST. SINCE  
AMERICAN MEDICAL ASSOCIATION HEADQUARTERS IN CHICAGO, WE  
HAVE NOT CONTACTED BUT CAN DO SO IF SCHEDULE WOULD ALLOW.

2. REGARDING PHARMACEUTICAL INDUSTRY CONTACTS, WE  
SUGGEST USEFUL FOR GROUP TO SEE PHARMACEUTICAL MANUFAC-  
TURERS ASSOCIATION(PMA) WHILE HERE. PMA WOULD WELCOME  
VISIT AND COULD HELP IN ARRANGING VISITS TO FIRMS. PMA  
ADVISES THAT THERE CLUSTER OF FIRMS IN NEW JERSEY WHICH  
UNCLASSIFIED

UNCLASSIFIED

PAGE 02 STATE 134799

COULD BE FAIRLY CONVENIENT AFTER WASHINGTON VISIT.

3. IN GENERAL SCHEDULE LOOKS QUITE TIGHT FOR COVERING  
ALL BASES PROPOSED. FOR EXAMPLE, FDA VISIT COULD  
USEFULLY BE ABOUT 1 1/2 DAYS. CONSIDERATION SHOULD BE  
GIVEN TO SLIGHTLY LONGER PERIOD. KISSINGER

UNCLASSIFIED

NNN

## Message Attributes

**Automatic Decaptioning:** X  
**Capture Date:** 01 JAN 1994  
**Channel Indicators:** n/a  
**Current Classification:** UNCLASSIFIED  
**Concepts:** DRUGS, ITINERARY, VISITS, COMMITTEES  
**Control Number:** n/a  
**Copy:** SINGLE  
**Draft Date:** 10 JUN 1975  
**Decaption Date:** 01 JAN 1960  
**Decaption Note:**  
**Disposition Action:** n/a  
**Disposition Approved on Date:**  
**Disposition Authority:** n/a  
**Disposition Case Number:** n/a  
**Disposition Comment:**  
**Disposition Date:** 01 JAN 1960  
**Disposition Event:**  
**Disposition History:** n/a  
**Disposition Reason:**  
**Disposition Remarks:**  
**Document Number:** 1975STATE134799  
**Document Source:** CORE  
**Document Unique ID:** 00  
**Drafter:** MBEAUBIEN  
**Enclosure:** n/a  
**Executive Order:** N/A  
**Errors:** N/A  
**Film Number:** D750202-0946  
**From:** STATE  
**Handling Restrictions:** n/a  
**Image Path:**  
**ISecure:** 1  
**Legacy Key:** link1975/newtext/t19750664/aaaacgjn.tel  
**Line Count:** 66  
**Locator:** TEXT ON-LINE, ON MICROFILM  
**Office:** ORIGIN OES  
**Original Classification:** UNCLASSIFIED  
**Original Handling Restrictions:** n/a  
**Original Previous Classification:** n/a  
**Original Previous Handling Restrictions:** n/a  
**Page Count:** 2  
**Previous Channel Indicators:** n/a  
**Previous Classification:** n/a  
**Previous Handling Restrictions:** n/a  
**Reference:** 75 BONN 8474  
**Review Action:** RELEASED, APPROVED  
**Review Authority:** greeneet  
**Review Comment:** n/a  
**Review Content Flags:**  
**Review Date:** 03 MAR 2003  
**Review Event:**  
**Review Exemptions:** n/a  
**Review History:** RELEASED <03 MAR 2003 by PhilliR0>; APPROVED <06 FEB 2004 by greeneet>  
**Review Markings:**

Margaret P. Grafeld  
Declassified/Released  
US Department of State  
EO Systematic Review  
06 JUL 2006

**Review Media Identifier:**  
**Review Referrals:** n/a  
**Review Release Date:** n/a  
**Review Release Event:** n/a  
**Review Transfer Date:**  
**Review Withdrawn Fields:** n/a  
**Secure:** OPEN  
**Status:** NATIVE  
**Subject:** U.S. PHARMACEUTICAL REGULATION: STUDY TOUR OF FRG PARLIAMENTARIANS  
**TAGS:** ETRD, TBIO, PINT, OTRA, GE  
**To:** BONN  
**Type:** TE  
**Markings:** Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 06 JUL 2006